Annual report

Period2022-01-01 → 2022-12-31

Filed2023-03-27

StandardJapan GAAP

ConsolidatedYes

Data checks24 of 24 passed

Key figures · 137

Metric	Value	Period	Scope	Source row
Revenue	¥1.4bn	2022-01-01 → 2022-12-31	Cons.	Net sales
Revenue	¥2.0bn	2021-01-01 → 2021-12-31	Cons.	Net sales
Revenue	¥1.1bn	2020-01-01 → 2020-12-31^d	Cons.	Net sales (5-year summary)
Revenue	¥3.2bn	2019-01-01 → 2019-12-31^d	Cons.	Net sales (5-year summary)
Revenue	¥755m	2018-01-01 → 2018-12-31^d	Cons.	Net sales (5-year summary)
Operating income	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Operating income
Operating income	−¥531m	2021-01-01 → 2021-12-31	Cons.	Operating income
Ordinary income	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Ordinary income
Ordinary income	−¥523m	2021-01-01 → 2021-12-31	Cons.	Ordinary income
Ordinary income	−¥1.1bn	2020-01-01 → 2020-12-31^d	Cons.	Ordinary income loss (5-year summary)
Ordinary income	¥957m	2019-01-01 → 2019-12-31^d	Cons.	Ordinary income loss (5-year summary)
Ordinary income	−¥1.2bn	2018-01-01 → 2018-12-31^d	Cons.	Ordinary income loss (5-year summary)
Profit before tax	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Income before income taxes
Profit before tax	−¥532m	2021-01-01 → 2021-12-31	Cons.	Income before income taxes
Net income (owners)	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Profit loss attributable to owners of parent
Net income (owners)	−¥534m	2021-01-01 → 2021-12-31	Cons.	Profit loss attributable to owners of parent
Net income (owners)	−¥1.1bn	2020-01-01 → 2020-12-31^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income (owners)	¥828m	2019-01-01 → 2019-12-31^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income (owners)	−¥1.2bn	2018-01-01 → 2018-12-31^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Profit loss
Net income	−¥534m	2021-01-01 → 2021-12-31	Cons.	Profit loss
Total assets	¥4.3bn	at 2022-12-31	Cons.	Assets
Total assets	¥5.4bn	at 2021-12-31	Cons.	Assets
Total assets	¥4.8bn	at 2020-12-31^d	Cons.	Total assets (5-year summary)
Total assets	¥5.4bn	at 2019-12-31^d	Cons.	Total assets (5-year summary)
Total assets	¥1.8bn	at 2018-12-31^d	Cons.	Total assets (5-year summary)
Total liabilities	¥625m	at 2022-12-31	Cons.	Liabilities
Total liabilities	¥1.1bn	at 2021-12-31	Cons.	Liabilities
Net assets / equity	¥3.6bn	at 2022-12-31	Cons.	Net assets
Net assets / equity	¥4.3bn	at 2021-12-31	Cons.	Net assets
Net assets / equity	¥3.8bn	at 2020-12-31^d	Cons.	Net assets
Net assets / equity	¥3.9bn	at 2019-12-31^d	Cons.	Net assets (5-year summary)
Net assets / equity	¥887m	at 2018-12-31^d	Cons.	Net assets (5-year summary)
Cash and deposits	¥3.4bn	at 2022-12-31	Cons.	Cash and deposits
Cash and deposits	¥3.8bn	at 2021-12-31	Cons.	Cash and deposits
Cash & equivalents	¥3.4bn	at 2022-12-31	Cons.	Cash and cash equivalents
Cash & equivalents	¥3.8bn	at 2021-12-31	Cons.	Cash and cash equivalents
Cash & equivalents	¥4.3bn	at 2020-12-31^d	Cons.	Cash and cash equivalents
Cash & equivalents	¥4.9bn	at 2019-12-31^d	Cons.	Cash and cash equivalents (5-year summary)
Cash & equivalents	¥1.4bn	at 2018-12-31^d	Cons.	Cash and cash equivalents (5-year summary)
Operating cash flow	−¥708m	2022-01-01 → 2022-12-31	Cons.	Net cash provided by used in operating activities
Operating cash flow	−¥1.5bn	2021-01-01 → 2021-12-31	Cons.	Net cash provided by used in operating activities
Operating cash flow	−¥1.3bn	2020-01-01 → 2020-12-31^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Operating cash flow	¥1.5bn	2019-01-01 → 2019-12-31^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Operating cash flow	−¥1.1bn	2018-01-01 → 2018-12-31^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Investing cash flow	−¥126m	2022-01-01 → 2022-12-31	Cons.	Net cash provided by used in investment activities
Investing cash flow	−¥42m	2021-01-01 → 2021-12-31	Cons.	Net cash provided by used in investment activities
Investing cash flow	−¥70m	2020-01-01 → 2020-12-31^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Investing cash flow	−¥41m	2019-01-01 → 2019-12-31^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Investing cash flow	−¥58m	2018-01-01 → 2018-12-31^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Financing cash flow	¥367m	2022-01-01 → 2022-12-31	Cons.	Net cash provided by used in financing activities
Financing cash flow	¥1.1bn	2021-01-01 → 2021-12-31	Cons.	Net cash provided by used in financing activities
Financing cash flow	¥724m	2020-01-01 → 2020-12-31^d	Cons.	Net cash provided by used in financing activities (5-year summary)
Financing cash flow	¥2.1bn	2019-01-01 → 2019-12-31^d	Cons.	Net cash provided by used in financing activities (5-year summary)
Financing cash flow	¥688m	2018-01-01 → 2018-12-31^d	Cons.	Net cash provided by used in financing activities (5-year summary)
EPS (basic)	¥-99.1	2022-01-01 → 2022-12-31	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-42.1	2021-01-01 → 2021-12-31	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-90.33	2020-01-01 → 2020-12-31^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥76.05	2019-01-01 → 2019-12-31^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-125.02	2018-01-01 → 2018-12-31^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (diluted)	¥74.51	2019-01-01 → 2019-12-31^d	Cons.	Diluted earnings per share (5-year summary)
Net assets per share	¥255.04	at 2022-12-31	Cons.	Net assets per share (5-year summary)
Net assets per share	¥323.54	at 2021-12-31	Cons.	Net assets per share (5-year summary)
Net assets per share	¥308.05	at 2020-12-31^d	Cons.	Net assets per share (5-year summary)
Net assets per share	¥329.86	at 2019-12-31^d	Cons.	Net assets per share (5-year summary)
Net assets per share	¥86.83	at 2018-12-31^d	Cons.	Net assets per share (5-year summary)
Equity ratio	85.0%	at 2022-12-31	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	79.3%	at 2021-12-31	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	79.0%	at 2020-12-31^d	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	71.5%	at 2019-12-31^d	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	49.7%	at 2018-12-31^d	Cons.	Equity to asset ratio (5-year summary)
ROE	35.1%	2019-01-01 → 2019-12-31^d	Cons.	Rate of return on equity (5-year summary)
Employees	65	at 2022-12-31	Cons.	Number of employees
Employees	64	at 2021-12-31	Cons.	Number of employees
Employees	64	at 2020-12-31^d	Cons.	Number of employees
Employees	63	at 2019-12-31^d	Cons.	Number of employees
Employees	62	at 2018-12-31^d	Cons.	Number of employees
Revenue	¥1.2bn	2022-01-01 → 2022-12-31	Standalone	Net sales
Revenue	¥1.9bn	2021-01-01 → 2021-12-31	Standalone	Net sales
Revenue	¥1.0bn	2020-01-01 → 2020-12-31^d	Standalone	Net sales (5-year summary)
Revenue	¥3.1bn	2019-01-01 → 2019-12-31^d	Standalone	Net sales (5-year summary)
Revenue	¥641m	2018-01-01 → 2018-12-31^d	Standalone	Net sales (5-year summary)
Operating income	−¥1.3bn	2022-01-01 → 2022-12-31	Standalone	Operating income
Operating income	−¥558m	2021-01-01 → 2021-12-31	Standalone	Operating income
Ordinary income	−¥1.4bn	2022-01-01 → 2022-12-31	Standalone	Ordinary income
Ordinary income	−¥549m	2021-01-01 → 2021-12-31	Standalone	Ordinary income
Ordinary income	−¥1.1bn	2020-01-01 → 2020-12-31^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	¥874m	2019-01-01 → 2019-12-31^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	−¥1.2bn	2018-01-01 → 2018-12-31^d	Standalone	Ordinary income loss (5-year summary)
Profit before tax	−¥1.4bn	2022-01-01 → 2022-12-31	Standalone	Income before income taxes
Profit before tax	−¥558m	2021-01-01 → 2021-12-31	Standalone	Income before income taxes
Net income	−¥1.4bn	2022-01-01 → 2022-12-31	Standalone	Profit loss
Net income	−¥556m	2021-01-01 → 2021-12-31	Standalone	Profit loss
Net income	−¥1.1bn	2020-01-01 → 2020-12-31^d	Standalone	Net income loss (5-year summary)
Net income	¥746m	2019-01-01 → 2019-12-31^d	Standalone	Net income loss (5-year summary)
Net income	−¥1.2bn	2018-01-01 → 2018-12-31^d	Standalone	Net income loss (5-year summary)
Total assets	¥4.0bn	at 2022-12-31	Standalone	Assets
Total assets	¥5.3bn	at 2021-12-31	Standalone	Assets
Total assets	¥4.7bn	at 2020-12-31^d	Standalone	Total assets (5-year summary)
Total assets	¥5.3bn	at 2019-12-31^d	Standalone	Total assets (5-year summary)
Total assets	¥1.8bn	at 2018-12-31^d	Standalone	Total assets (5-year summary)
Total liabilities	¥607m	at 2022-12-31	Standalone	Liabilities
Total liabilities	¥1.1bn	at 2021-12-31	Standalone	Liabilities
Net assets / equity	¥3.4bn	at 2022-12-31	Standalone	Net assets
Net assets / equity	¥4.2bn	at 2021-12-31	Standalone	Net assets
Net assets / equity	¥3.7bn	at 2020-12-31^d	Standalone	Net assets
Net assets / equity	¥3.8bn	at 2019-12-31^d	Standalone	Net assets (5-year summary)
Net assets / equity	¥900m	at 2018-12-31^d	Standalone	Net assets (5-year summary)
Cash and deposits	¥3.1bn	at 2022-12-31	Standalone	Cash and deposits
Cash and deposits	¥3.6bn	at 2021-12-31	Standalone	Cash and deposits
EPS (basic)	¥-103.2	2022-01-01 → 2022-12-31	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-43.83	2021-01-01 → 2021-12-31	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-91.84	2020-01-01 → 2020-12-31^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥68.47	2019-01-01 → 2019-12-31^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-123.85	2018-01-01 → 2018-12-31^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (diluted)	¥67.08	2019-01-01 → 2019-12-31^d	Standalone	Diluted earnings per share (5-year summary)
Net assets per share	¥240.82	at 2022-12-31	Standalone	Net assets per share (5-year summary)
Net assets per share	¥314.45	at 2021-12-31	Standalone	Net assets per share (5-year summary)
Net assets per share	¥301.39	at 2020-12-31^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥323.68	at 2019-12-31^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥88.07	at 2018-12-31^d	Standalone	Net assets per share (5-year summary)
Equity ratio	84.6%	at 2022-12-31	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	78.9%	at 2021-12-31	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	78.7%	at 2020-12-31^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	71.1%	at 2019-12-31^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	50.1%	at 2018-12-31^d	Standalone	Equity to asset ratio (5-year summary)
ROE	32.0%	2019-01-01 → 2019-12-31^d	Standalone	Rate of return on equity (5-year summary)
Shares issued	14,218,300	at 2022-12-31	Standalone	Total number of issued shares (5-year summary)
Shares issued	13,313,400	at 2021-12-31	Standalone	Total number of issued shares (5-year summary)
Shares issued	12,407,100	at 2020-12-31^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	11,654,500	at 2019-12-31^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	10,139,600	at 2018-12-31^d	Standalone	Total number of issued shares (5-year summary)
Employees	62	at 2022-12-31	Standalone	Number of employees
Employees	61	at 2021-12-31	Standalone	Number of employees
Employees	61	at 2020-12-31^d	Standalone	Number of employees
Employees	60	at 2019-12-31^d	Standalone	Number of employees
Employees	58	at 2018-12-31^d	Standalone	Number of employees

Periods use the dates stated in the filing. ^d = earlier-year period dated by calendar; ^v = that date confirmed by the company's own earlier filing.

Segments · 42

Segment	Item	Period	Value
Reconciling Itemsreconciling	segment assets	at 2022-12-31	¥3.2bn
Drug Discovery Businessreportable segment	capex	2022-01-01 → 2022-12-31	¥68m
Drug Discovery Businessreportable segment	depreciation	2022-01-01 → 2022-12-31	¥13m
Drug Discovery Businessreportable segment	employees	at 2022-12-31	34 pure
Drug Discovery Businessreportable segment	revenue	2022-01-01 → 2022-12-31	¥286m
Drug Discovery Businessreportable segment	revenue external	2022-01-01 → 2022-12-31	¥286m
Drug Discovery Businessreportable segment	segment assets	at 2022-12-31	¥373m
Drug Discovery Businessreportable segment	segment profit	2022-01-01 → 2022-12-31	−¥1.7bn
Drug Discovery Support Businessreportable segment	capex	2022-01-01 → 2022-12-31	¥58m
Drug Discovery Support Businessreportable segment	depreciation	2022-01-01 → 2022-12-31	¥21m
Drug Discovery Support Businessreportable segment	employees	at 2022-12-31	23 pure
Drug Discovery Support Businessreportable segment	revenue	2022-01-01 → 2022-12-31	¥1.1bn
Drug Discovery Support Businessreportable segment	revenue external	2022-01-01 → 2022-12-31	¥1.1bn
Drug Discovery Support Businessreportable segment	segment assets	at 2022-12-31	¥685m
Drug Discovery Support Businessreportable segment	segment profit	2022-01-01 → 2022-12-31	¥453m
—segment total	capex	2022-01-01 → 2022-12-31	¥126m
—segment total	depreciation	2022-01-01 → 2022-12-31	¥34m
—segment total	revenue	2022-01-01 → 2022-12-31	¥1.4bn
—segment total	revenue external	2022-01-01 → 2022-12-31	¥1.4bn
—segment total	segment assets	at 2022-12-31	¥1.1bn
—segment total	segment profit	2022-01-01 → 2022-12-31	−¥1.3bn
Reconciling Itemsreconciling	segment assets	at 2021-12-31	¥3.7bn
Drug Discovery Businessreportable segment	capex	2021-01-01 → 2021-12-31	¥14m
Drug Discovery Businessreportable segment	depreciation	2021-01-01 → 2021-12-31	¥5m
Drug Discovery Businessreportable segment	revenue	2021-01-01 → 2021-12-31	¥1.1bn
Drug Discovery Businessreportable segment	revenue external	2021-01-01 → 2021-12-31	¥1.1bn
Drug Discovery Businessreportable segment	segment assets	at 2021-12-31	¥1.2bn
Drug Discovery Businessreportable segment	segment profit	2021-01-01 → 2021-12-31	−¥820m
Drug Discovery Support Businessreportable segment	capex	2021-01-01 → 2021-12-31	¥12m
Drug Discovery Support Businessreportable segment	depreciation	2021-01-01 → 2021-12-31	¥15m
Drug Discovery Support Businessreportable segment	revenue	2021-01-01 → 2021-12-31	¥890m
Drug Discovery Support Businessreportable segment	revenue external	2021-01-01 → 2021-12-31	¥890m
Drug Discovery Support Businessreportable segment	segment assets	at 2021-12-31	¥497m
Drug Discovery Support Businessreportable segment	segment profit	2021-01-01 → 2021-12-31	¥289m
—segment total	capex	2021-01-01 → 2021-12-31	¥26m
—segment total	depreciation	2021-01-01 → 2021-12-31	¥19m
—segment total	revenue	2021-01-01 → 2021-12-31	¥2.0bn
—segment total	revenue external	2021-01-01 → 2021-12-31	¥2.0bn
—segment total	segment assets	at 2021-12-31	¥1.7bn
—segment total	segment profit	2021-01-01 → 2021-12-31	−¥531m
Drug Discovery Businessreportable segment	employees	at 2022-12-31	33 pure
Drug Discovery Support Businessreportable segment	employees	at 2022-12-31	21 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,303

Item	Context	Value
Description of business (text)	FilingDateInstant	Text · Plus
Overview of affiliated entities (text)	FilingDateInstant	Text · Plus
Information about employees (text)	FilingDateInstant	Text · Plus
Business policy business environment issues to address etc (text)	FilingDateInstant	Text · Plus
Business risks (text)	FilingDateInstant	Text · Plus
Material matters relating to going concern etc business risks (text)	FilingDateInstant	Text · Plus
Management analysis of financial position operating results and cash flows (text)	FilingDateInstant	Text · Plus
Critical contracts for operation (text)	FilingDateInstant	Text · Plus
Research and development activities (text)	FilingDateInstant	Text · Plus
Overview of capital expenditures etc (text)	FilingDateInstant	Text · Plus
Major facilities (text)	FilingDateInstant	Text · Plus
Planned additions retirements etc of facilities (text)	FilingDateInstant	Text · Plus
Total number of shares (text)	FilingDateInstant	Text · Plus
Issued shares total number of shares etc (text)	FilingDateInstant	Text · Plus
Class issued shares total number of shares etc	FilingDateInstant_OrdinaryShareMember	Original text (Japanese) 普通株式
Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered	FilingDateInstant_OrdinaryShareMember	Original text (Japanese) 東京証券取引所グロース市場
Description issued shares total number of shares etc	FilingDateInstant_OrdinaryShareMember	Original text (Japanese) （注）1
Details of employee share option program (text)	FilingDateInstant	Text · Plus
Description of rights plan (text)	FilingDateInstant	Text · Plus
Other information on share acquisition rights (text)	FilingDateInstant	Text · Plus
Exercises etc of moving strike convertible bonds etc (text)	FilingDateInstant	Text · Plus
Changes in number of issued shares stated capital etc (text)	FilingDateInstant	Text · Plus
Shareholding by shareholder category (text)	FilingDateInstant	Text · Plus
Major shareholders (text)	FilingDateInstant	Text · Plus
Name major shareholders	CurrentYearInstant_No1MajorShareholdersMember	Original text (Japanese) 小野薬品工業株式会社
Address major shareholders	CurrentYearInstant_No1MajorShareholdersMember	Original text (Japanese) 大阪府大阪市中央区道修町2丁目1番5号
Name major shareholders	CurrentYearInstant_No2MajorShareholdersMember	Text · Plus
Address major shareholders	CurrentYearInstant_No2MajorShareholdersMember	AIB INTERNATIONAL CENTRE P.O. BOX 518 IFSC DUBLIN, IRELAND
Name major shareholders	CurrentYearInstant_No3MajorShareholdersMember	Original text (Japanese) MSIP CLIENT SECURITIES （常任代理人　モルガン・スタンレーMUFG証券株式会社）
Address major shareholders	CurrentYearInstant_No3MajorShareholdersMember	25 CABOT SQUARE, CANARY WHARF, LONDON E14 4QA, U.K.
Name major shareholders	CurrentYearInstant_No4MajorShareholdersMember	Original text (Japanese) 株式会社SBI証券
Address major shareholders	CurrentYearInstant_No4MajorShareholdersMember	Original text (Japanese) 東京都港区六本木1丁目6番1号
Name major shareholders	CurrentYearInstant_No5MajorShareholdersMember	Original text (Japanese) 吉野　公一郎
Address major shareholders	CurrentYearInstant_No5MajorShareholdersMember	Original text (Japanese) 大阪府吹田市
Name major shareholders	CurrentYearInstant_No6MajorShareholdersMember	Original text (Japanese) 上原　俊彦
Address major shareholders	CurrentYearInstant_No6MajorShareholdersMember	Original text (Japanese) 東京都港区
Name major shareholders	CurrentYearInstant_No7MajorShareholdersMember	Text · Plus
Address major shareholders	CurrentYearInstant_No7MajorShareholdersMember	2 KING EDWARD STREET, LONDON EC1A 1HQ, U.K.
Name major shareholders	CurrentYearInstant_No8MajorShareholdersMember	Text · Plus
Address major shareholders	CurrentYearInstant_No8MajorShareholdersMember	ONE CHURCHILL PLACE, LONDON E14 5HP, U.K.
Name major shareholders	CurrentYearInstant_No9MajorShareholdersMember	Text · Plus
Address major shareholders	CurrentYearInstant_No9MajorShareholdersMember	PETERBOROUGH COURT 133, FLEET STREET LONDON EC4A 2BB U.K.
Name major shareholders	CurrentYearInstant_No10MajorShareholdersMember	Original text (Japanese) JPモルガン証券株式会社
Address major shareholders	CurrentYearInstant_No10MajorShareholdersMember	Original text (Japanese) 東京都千代田区丸の内2丁目7-3東京ビルディング
Issued shares voting rights (text)	FilingDateInstant	Text · Plus
Description issued shares voting rights	CurrentYearInstant_SharesWithNoVotingRightsMember	－
Description issued shares voting rights	CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember	－
Description issued shares voting rights	CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember	－
Description issued shares voting rights	CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember	Original text (Japanese) 自己保有株式
Description issued shares voting rights	CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember	Original text (Japanese) 権利内容に何ら限定のない当社における標準的となる株式

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed

balance sheet identity	consolidated 2021-12-31	pass
balance sheet identity	consolidated 2022-12-31	pass
balance sheet identity	non_consolidated 2021-12-31	pass rounding
balance sheet identity	non_consolidated 2022-12-31	pass
dei present		pass
period resolution		pass
statement vs summary · net assets	consolidated 2020-12-31	pass
statement vs summary · net assets	consolidated 2021-12-31	pass
statement vs summary · net assets	consolidated 2022-12-31	pass
statement vs summary · net assets	non_consolidated 2020-12-31	pass
statement vs summary · net assets	non_consolidated 2021-12-31	pass
statement vs summary · net assets	non_consolidated 2022-12-31	pass
statement vs summary · net income attributable to parent	consolidated 2021-01-01/2021-12-31	pass
statement vs summary · net income attributable to parent	consolidated 2022-01-01/2022-12-31	pass
statement vs summary · operating cash flow	consolidated 2021-01-01/2021-12-31	pass
statement vs summary · operating cash flow	consolidated 2022-01-01/2022-12-31	pass
statement vs summary · revenue	consolidated 2021-01-01/2021-12-31	pass
statement vs summary · revenue	consolidated 2022-01-01/2022-12-31	pass
statement vs summary · revenue	non_consolidated 2021-01-01/2021-12-31	pass
statement vs summary · revenue	non_consolidated 2022-01-01/2022-12-31	pass
statement vs summary · total assets	consolidated 2021-12-31	pass
statement vs summary · total assets	consolidated 2022-12-31	pass
statement vs summary · total assets	non_consolidated 2021-12-31	pass
statement vs summary · total assets	non_consolidated 2022-12-31	pass